Search

everythinglearnresearchcommunity

for

Search:↓

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Reducing gefitinib dosage improved hair loss, but scarring remained.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Enhanced stem cells from the placenta can reduce fat buildup in eye tissue for Graves' disease.

Metformin combined with dyne-35 increases ovulation and pregnancy rates in PCOS patients.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

JAK inhibitors are effective and safe for treating severe alopecia areata.

A specific gene mutation is linked to a hereditary form of dystonia that responds well to certain medications.

Tofacitinib may help treat severe hair loss, but more research is needed.

The model successfully predicted new uses for existing drugs, like using certain hormonal and heart medications for respiratory and Parkinson's diseases, and a cancer drug for diabetes.

A new metformin-based treatment may effectively promote hair growth with fewer side effects.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

The study developed accurate, precise, and environmentally friendly methods to measure Finasteride and Tadalafil in a new FDA-approved combination.

Compounds in fluted pumpkin and African yam bean seed oils may help manage benign prostate hyperplasia.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

GT20029 showed some hair growth improvement, but longer studies are needed for better results.

Glycated hemoglobin is not as effective as the oral glucose tolerance test for diagnosing blood sugar problems in women with PCOS in Southern Iraq.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

Type B Insulin Resistance Syndrome is rare, linked to lupus, and hard to treat due to severe insulin resistance.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Baricitinib improved nail condition and hair regrowth in a patient with alopecia and nail abnormalities.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

Deucravacitinib helped a man regrow hair significantly.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.